GlycoErase™ ALG9 Knockout Human Skin Cancer Cell A2058 (CAT#: GLJF-0525-JF902)

Description	The ALG9 deficient A2058 cell line is a valuable resource for evaluating the consequences of lipid-linked oligosaccharide assembly defects in the context of cutaneous melanoma, where the absence of ALG9 disrupts N-glycosylation, facilitating the study of associations between N-glycosylation abnormalities and melanoma development, progression, metastasis, and the exploration of ALG9-targeted therapeutic approaches.
Product Type	KO Cell Lines
Species	Human
Cell Morphology	Epithelial cells, adherent
Passage Ratio	1:2~1:3
Cell Line	A2058
Primary Disease	Melanoma
Lineage	Skin

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Culture Medium	EMEM & FBS & Glutamine
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	ALG9
Full Name	ALG9 alpha-1,2-mannosyltransferase
Alternative Name	DIBD1
Location	11q23.1
Gene ID	79796
Summary	Facilitates lipid-linked oligosaccharide assembly; mutations lead to CDG II (congenital disorder of glycosylation type II); multiple transcript variants (different isoforms) may influence enzyme specificity.